Try our Advanced Search for more refined results
Life Sciences
-
March 17, 2026
Fenwick Healthcare Regulatory Atty Rejoins Latham In LA
Latham & Watkins LLP is boosting its healthcare team, announcing Monday it is welcoming back a Fenwick & West LLP healthcare regulatory expert as a partner in its Los Angeles office.
-
March 16, 2026
1st Circ. Affirms Block Of Trump's 'Unprecedented' Aid Freeze
The First Circuit on Monday mostly upheld a lower court's order blocking the Trump administration from enacting a "sweeping and unprecedented categorical 'freeze' of federal financial assistance," ruling that the states involved in the suit will likely successfully show that the federal government acted arbitrarily and capriciously.
-
March 16, 2026
Judge Tosses Kaiser Whistleblowers' Claims After $556M Deal
A California federal court on Monday officially dismissed False Claims Act lawsuits from the federal government and three people alleging that Kaiser Permanente affiliates engaged in Medicare fraud, on the heels of Kaiser's $556 million settlement reached in January.
-
March 16, 2026
Lannett Investors Seek Final OK Of $5.8M Price-Fix Probe Suit
Former executives of pharmaceutical company Lannett Inc. and a class of investors have asked a Pennsylvania federal court to grant final approval to their $5.8 million deal to end claims the company and its leadership misled about Lannett's links to allegations of industrywide price-fixing in the market for generic drugs.
-
March 16, 2026
J&J's Lack Of Malice Gets $966M Talc Verdict Cut To $16M
A California state judge slashed $950 million in punitive damages from a $966 million jury verdict against Johnson & Johnson on Friday in a lawsuit involving an 88-year-old woman who died of mesothelioma, saying the estate's counsel failed to sufficiently show the pharmaceutical giant acted maliciously.
-
March 16, 2026
Medtronic Seeks To Ax 'Extreme Outlier' $382M Antitrust Loss
Medtronic has urged a California federal judge to scrap its nearly $382 million trial loss to rival Applied Medical over Medtronic's bundling practices that a jury found suppressed competition for advanced bipolar devices, arguing the verdict is an "extreme outlier" in antitrust law that can't survive.
-
March 16, 2026
Amgen And Sanofi End Repatha IP Fight Heard By Justices
Amgen Inc. and Sanofi have settled patent litigation over competing cholesterol drugs Repatha and Praluent, more than two years after they dueled at the U.S. Supreme Court, Sanofi confirmed Monday.
-
March 16, 2026
Italy's Amplifon Buying Danish Hearing Device Biz For $2.6B
Italy's Amplifon said Monday it has agreed to acquire the hearing device business of Denmark's GN Store Nord in a deal valuing the unit at about €2.3 billion ($2.6 billion), in a move aimed at creating a vertically integrated global leader in audiology.
-
March 16, 2026
HHS' Childhood Vaccine Policy Changes Put On Ice
A Massachusetts federal judge on Monday blocked the Trump administration's modified childhood vaccine schedule and put all decisions made by Health Secretary Robert F. Kennedy Jr.'s federal vaccine policy committee on hold, finding they veered sharply from normal procedure and likely violated the law.
-
March 16, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court's docket last week featured disputes including an $83.75 million settlement tied to a renewable energy merger, fraud claims in a fertilizer company acquisition and a developer's fight for control of a major Philadelphia redevelopment project.
-
March 13, 2026
AIG Policy Excludes $150M Pollution Coverage, 7th Circ. Finds
A Seventh Circuit panel on Friday ruled an AIG unit has no duty to cover $150 million in legal costs for Sterigenics and its former parent company following input from the Illinois Supreme Court on how to apply a pollution exclusion in the relevant policy.
-
March 13, 2026
Maryland Bros. Get Prison For HIV Drug Fraud Scheme
A Florida federal judge on Friday sentenced two Maryland brothers to prison for their roles in a fraudulent medication scheme that involved selling misbranded HIV drugs with fake tracing documents to pharmacies and patients.
-
March 13, 2026
She Has A Point: Finnegan's Cora Holt
Cora Holt, a partner at Finnegan Henderson Farabow Garrett & Dunner LLP in Washington, D.C., has a "do your job" attitude and "getting the stuff done" approach to litigation that earned plaudits from Kassie Helm, co-chair of Dechert LLP, who praised Holt for her work as part of a Law360 series celebrating women litigators.
-
March 13, 2026
Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit
Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.
-
March 13, 2026
4th Circ. Brings Back Allergan Medicaid Overcharging Suit
A split Fourth Circuit panel on Friday revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid by more than $680 million, saying the whistleblower plausibly alleged the company knowingly improperly aggregated discounts into "best prices" for drugs.
-
March 13, 2026
Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar
Sandoz Inc. is appealing after a Virginia federal court ruled it should have brought claims accusing Amgen of blocking competition for the Enbrel biosimilar in a previous patent dispute, according to a Friday notice.
-
March 13, 2026
Kroger Agrees To Pay $17M In Drug Copay Inflation Case
Kroger pharmacy customers reached a $17 million settlement with the grocer resolving allegations that it inflated their copays for insured prescriptions, according to a motion for preliminary approval of the deal filed in Ohio federal court.
-
March 13, 2026
Life Sciences Partner Hiring Up Amid Regulatory Scrutiny
Large law firms' partner additions in life sciences rose slightly across five geographic markets between 2024 and 2025, with several factors including increased regulatory scrutiny driving new additions, according to an analysis by intelligence platform Macrae+.
-
March 13, 2026
J&J Unit Says Ex-Director Misappropriated Trade Secrets
A Johnson & Johnson subsidiary has accused a former associate director of downloading over 7,000 files worth of confidential information prior to her resignation and using it to start her own competing company.
-
March 12, 2026
Orthopedics Co. Investors See Merger Claims Trimmed
Orthofix Medical Inc. must face claims that it failed to tell investors that a company it was merging with recently settled class action discrimination allegations, but will not have to face some securities fraud allegations, a Texas federal judge has ruled.
-
March 12, 2026
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs
The D.C. Circuit spent more than three hours Thursday going round with Vanda Pharmaceuticals and the U.S. Food and Drug Administration about whether the label for a generic sleep-wake disorder medication is "the same" as the branded one because it doesn't include Braille.
-
March 12, 2026
Tom's Toothpaste Trims Class Action Over Lead Levels
Tom's of Maine can't beat back proposed class claims it allowed heavy metals to taint its children's toothpaste, a New York federal judge ruled Wednesday, finding that the parent behind the suit adequately claimed the company falsely marketed the products as "safe" and "healthy."
-
March 12, 2026
IP Notebook: TM Use Fight, Popeye, Kurt Cobain
This edition of emerging copyright and trademark cases and trends looks at an appeal before the U.S. Supreme Court that questions the definition of trademark "use in commerce" under the Lanham Act and a battle over the use of "Popeye" as a trademark.
-
March 12, 2026
Embryo Loss Suits Need 'Serious' Edits, Judge Told
Two complaints against fertility products maker CooperSurgical Inc. require "serious" amendments to clarify the nature of the claims that a defective culture medium caused embryo losses for in vitro fertilization patients, the company told a Connecticut federal judge Thursday.
-
March 12, 2026
US Chamber Report Warns Of Risks To IP Protection
While the U.S. has ranked at the top of the U.S. Chamber of Commerce's list measuring how countries worldwide are enforcing intellectual property laws, the group said problems with free trade agreements and efforts to reduce pharmaceutical prices could cause problems on the horizon domestically.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
The Benefits Of Choosing A Niche Practice In The AI Age
As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.
-
How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.
-
What New Animal Welfare Enforcement Push Means For Cos.
The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.
-
How To Engage With Gov't's Direct-To-Consumer Drug Policy
The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.
-
Series
Podcasting Makes Me A Better Lawyer
Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.
-
Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts
Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.
-
Tax Court Ruling Signals Cross-Border Loan Scrutiny
The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.
-
Lessons From Justices' Split On Major Questions Doctrine
The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.
-
Drug Wholesaler's DPA Shows Imperfect Efforts Still Count
Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.
-
Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot
The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.
-
When MDLs Drag, State Courts Can Speed Mass Tort Results
Understanding the structural dynamics that can delay resolution in multidistrict litigation is essential to understanding why a state court strategy is sometimes not merely attractive, but necessary for plaintiffs seeking timely and just outcomes, say attorneys at DiCello Levitt.
-
Leveraging MDLs And State Courts In Mass Tort Strategy
Multidistrict litigation's quiet drift from a pretrial coordination device to a de facto national court for mass torts poses a strategic question for plaintiffs counsel — whether an MDL will yield timely trials, meaningful accountability and fair value for clients, or whether a state court strategy will be more effective, say attorneys at DiCello Levitt.
-
Unique Issues Facing Brand-Compounder Patent Litigation
Recent litigation and potential enforcement action against Hims & Hers Health raise questions about how compounders and branded pharmaceuticals companies would be positioned in patent litigation as compared to generics companies, which would require strategies different from those that would be used in traditional Hatch-Waxman Act litigation, say attorneys at Morgan Lewis.
-
Series
Volunteering With Scouts Makes Me A Better Lawyer
Serving as an assistant scoutmaster for my son’s troop reaffirmed several skills and principles crucial to lawyering — from the importance of disconnecting to the value of morality, says Michael Warren at McManis Faulkner.
-
Series
Law School's Missed Lessons: In Court, It's About Storytelling
Law school provides doctrine, cases and hypotheticals, but when lawyers step into the courtroom, they must learn the importance of clarity, credibility, memorability and preparation — in other words, how to tell simple, effective stories, say Nicholas Steverson and Danielle Trujillo at Wheeler Trigg, and Lisa DeCaro at Courtroom Performance.